PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging markers. …

Our objective was to determine the optimal approach for assessing amyloid disease in a
cognitively normal elderly population. Methods: Dynamic 18 F-flutemetamol PET scans were …

Background In vivo, high cerebral amyloid-β load has been associated with (i) reduced
concentrations of Aβ 42 in cerebrospinal fluid and (ii) increased retention using amyloid-β …

Objective To investigate the association between discordant β-amyloid (Aβ) PET and CSF
biomarkers at baseline and the emergence of tau pathology 5 years later. Methods We …

Purpose We aimed to investigate associations between tau pathology and relative cerebral
blood flow (rCBF), and their relationship with cognition in Alzheimer’s disease (AD), by using …

Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology
and grade its extent | European Journal of Nuclear Medicine and Molecular Imaging Skip to …

Background Amyloid-β PET and CSF Aβ 42 yield discordant results in 10–20% of memory
clinic patients, possibly providing unique information. Although the predictive power of …

Objective Accumulation of amyloid‐β is among the earliest changes in Alzheimer’s disease (AD).
Amyloid‐β positron emission tomography (PET) and Aβ 42 in cerebrospinal fluid (CSF) …

Background: Amyloid-ß positron emission tomography (PET) and cerebrospinal fluid (CSF)
Aß42 are considered interchangeable for clinical diagnosis of Alzheimer’s disease. Objective…

OBJECTIVE To investigate the association between discordant amyloid-β PET and CSF
biomarkers at baseline and the emergence of tau pathology 5 years later. METHODS We …